[Encore] What the industry is (still) getting wrong about value-based care
Listen now
Description
(This episode originally aired on September 26, 2023.) Value-based care has been dominating industry conversations in recent years. Here on Radio Advisory, we talk a lot about best practices, how to make the right investments, and how to best prepare leaders for the future of value-based care. But given all this momentum, we want to spend time asking the question: what are the misconceptions or misaligned expectations that leaders have around value-based care? In this episode, host Rachel (Rae) Woods invites Advisory Board value-based care expert Daniel Kuzmanovich and Optum Advisory Service's SVP of value-based care, Erik Johnson, to discuss the mindset shifts they think leaders should be making when pursuing a sustainable value-based care strategy. Throughout the conversation they discuss what leaders are currently getting wrong, how myths about value-based care are impacting the industry, and more. Links: Our Value-based Care playlist Ep. 172: Build a value-based enterprise: Live from 2023 Value-Based Care Summit Ep. 126: [Bonus content] Commercial risk is possible—here's how How Health Plans Can Support Providers in Risk The climb to value-based care 3 strategies for a successful sleep apnea therapy program: Lessons from ENTTX's ASC partnership Strategic Planner's survey 2024 Survey insights: 6 priorities for health system strategists in 2024 Advisory Board is a subsidiary of Optum. All Advisory Board research, expert perspectives, and recommendations remain independent.
More Episodes
In the midst of the COVID-19 pandemic, The Centers for Medicare & Medicaid services released the Acute Hospital Care at Home payment waiver. The action was expected to usher in a new era of home-based care. But while it’s certainly grown in recent years, frankly, that massive shift hasn’t...
Published 09/24/24
Published 09/24/24
In the last few years, all eyes have turned to GLP-1s as an industry-altering answer to obesity treatment and weight management. But the fact is, these drugs can’t – and shouldn’t – work in a vacuum. There is a fear that attention on GLP-1s may even blind leaders to the other services that go...
Published 09/10/24